Barclays Starts Protagonist Therapeutics (PTGX) at Overweight

Barclays analyst Etzer Darout initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Overweight rating and a price target of $72.00.

The analyst comments "We initiate coverage of Protagonist Therapeutics with an Overweight rating and a $72 price target. Protagonist is leveraging its peptide technology platform to address hematology, immunology and metabolic disorders and we expect PTGX shares to continue to appreciate on regulatory milestones in 2026 and clinical de-risking of its pipeline over the next 12 months with important catalysts across its pipeline. Protagonist's oral peptide platform has received initial validation with the clinical success in psoriasis with JNJ-2113 (oral IL-23), and PTGX expects to move its second oral peptide (IL-17) into the clinic in the fourth quarter. We believe Protagonist can deliver oral options in mega-blockbuster categories currently dominated by injectables."

For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.

Shares of Protagonist Therapeutics closed at $58.38 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'